Posted on 05/12/06
Pfizer share value sinks $21-billion as key drug halted
WASHINGTON -- Pfizer Inc.'s shares fell 11 per cent yesterday, wiping out $21-billion (U.S.) of market value, after the world's biggest drug maker ended development of its most important new treatment, a cholesterol medicine designed to replace Lipitor when its patent expires.
The full text of this article has 502 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
